These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 38170544)

  • 1. Sickle Cell Disease Approvals Include First CRISPR Gene Editing Therapy.
    Harris E
    JAMA; 2024 Jan; 331(4):280. PubMed ID: 38170544
    [No Abstract]   [Full Text] [Related]  

  • 2. Discontinued CRISPR gene therapy for sickle-cell disease improves symptoms.
    Carvalho T
    Nat Med; 2023 Nov; 29(11):2669-2670. PubMed ID: 37783810
    [No Abstract]   [Full Text] [Related]  

  • 3. Cellular function reinstitution of offspring red blood cells cloned from the sickle cell disease patient blood post CRISPR genome editing.
    Wen J; Tao W; Hao S; Zu Y
    J Hematol Oncol; 2017 Jun; 10(1):119. PubMed ID: 28610635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.
    Meisel R
    N Engl J Med; 2021 Jun; 384(23):e91. PubMed ID: 34107195
    [No Abstract]   [Full Text] [Related]  

  • 5. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.
    Mehta J
    N Engl J Med; 2021 Jun; 384(23):e91. PubMed ID: 34107196
    [No Abstract]   [Full Text] [Related]  

  • 6. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia. Reply.
    Frangoul H; Ho TW; Corbacioglu S
    N Engl J Med; 2021 Jun; 384(23):e91. PubMed ID: 34107197
    [No Abstract]   [Full Text] [Related]  

  • 7. Perspectives of Sickle Cell Disease Stakeholders on Heritable Genome Editing.
    Hollister BM; Gatter MC; Abdallah KE; Armsby AJ; Buscetta AJ; Byeon YJJ; Cooper KE; Desine S; Persaud A; Ormond KE; Bonham VL
    CRISPR J; 2019 Dec; 2(6):441-449. PubMed ID: 31742431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia.
    Parums DV
    Med Sci Monit; 2024 Mar; 30():e944204. PubMed ID: 38425279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating Genetic Disorders Using State-Of-The-Art Technology.
    Jamal M; Ullah A; Ahsan M; Tyagi R; Habib Z; Khan FA; Rehman K
    Curr Issues Mol Biol; 2018; 26():33-46. PubMed ID: 28879854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR Therapy of Sickle Cell Disease: The Dawning of the Gene Editing Era.
    Adashi EY; Gruppuso PA; Cohen IG
    Am J Med; 2024 May; 137(5):390-392. PubMed ID: 38184185
    [No Abstract]   [Full Text] [Related]  

  • 11. Approval of the First CRISPR-Cas9 Gene Editing Therapy for Sickle Cell Disease.
    Campbell ST
    Clin Chem; 2024 Oct; 70(10):1298. PubMed ID: 39360998
    [No Abstract]   [Full Text] [Related]  

  • 12. CRISPR-Cas9 and Its Therapeutic Applications for Retinal Diseases.
    Lin WV; Stout JT; Weng CY
    Int Ophthalmol Clin; 2019; 59(1):3-13. PubMed ID: 30585915
    [No Abstract]   [Full Text] [Related]  

  • 13. Tweaking genes with CRISPR or viruses fixes blood disorders.
    Kaiser J
    Science; 2020 Dec; 370(6522):1254-1255. PubMed ID: 33303593
    [No Abstract]   [Full Text] [Related]  

  • 14. CRISPR gene therapy shows promise against blood diseases.
    Ledford H
    Nature; 2020 Dec; 588(7838):383. PubMed ID: 33299166
    [No Abstract]   [Full Text] [Related]  

  • 15. Ji Luo Elucidates the CRISPR Gene Editing Technology, and How It May Affect Cancer Therapy in the Future.
    Luo J
    Oncology (Williston Park); 2016 Oct; 30(10):879. PubMed ID: 27753053
    [No Abstract]   [Full Text] [Related]  

  • 16. In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges.
    Mout R; Ray M; Lee YW; Scaletti F; Rotello VM
    Bioconjug Chem; 2017 Apr; 28(4):880-884. PubMed ID: 28263568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [CRISPR-Cas system as molecular scissors for gene therapy].
    Heinz GA; Mashreghi MF
    Z Rheumatol; 2017 Feb; 76(1):46-49. PubMed ID: 28124743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imagine CRISPR cures.
    Urnov FD
    Mol Ther; 2021 Nov; 29(11):3103-3106. PubMed ID: 34710352
    [No Abstract]   [Full Text] [Related]  

  • 19. Genome Editing for Sickle Cell Disease: A Little BCL11A Goes a Long Way.
    Hossain MA; Bungert J
    Mol Ther; 2017 Mar; 25(3):561-562. PubMed ID: 28190778
    [No Abstract]   [Full Text] [Related]  

  • 20. Rationally Designed Base Editors for Precise Editing of the Sickle Cell Disease Mutation.
    Chu SH; Packer M; Rees H; Lam D; Yu Y; Marshall J; Cheng LI; Lam D; Olins J; Ran FA; Liquori A; Gantzer B; Decker J; Born D; Barrera L; Hartigan A; Gaudelli N; Ciaramella G; Slaymaker IM
    CRISPR J; 2021 Apr; 4(2):169-177. PubMed ID: 33876959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.